|New from NCI|
|Clinical Trials Support Approval for New Immunotherapy Options for Non-Small Cell Lung Cancer|
|The Food and Drug Administration (FDA) has approved an immunotherapy drug for some patients with non-small cell lung cancer and expanded the approval of another immunotherapy drug for non-small cell lung cancer so it is now a treatment option for more patients.|
|Video of Facebook Live Event Now Available|
|If you missed our Facebook Live Event on November 17 about immunotherapy clinical trials for lung cancer, the video recording is now available.|
|Device May Predict Response to Treatment|
Scientists have designed a device that measures the mass of single cancer cells to predict how cells respond to drug treatment. The technology may help clinicians determine which drugs may be most effective for an individual patient.
|NCI Clinical Trial Recruiting Patients with Newly Diagnosed Prostate Cancer|
In this study, men with prostate cancer will be treated with drugs that block the production and activity of the male hormone androgen. The purpose is to identify which men are most likely to benefit from the therapy before surgery to remove the prostate. This study is taking place at the NIH Clinical Center in Bethesda, Maryland.
|Drug Information Updates|
|CEV Combination to Treat Retinoblastoma|
We’ve added a new summary about the drug combination called CEV. It is used in children to treat retinoblastoma (cancer in the retina). The combination includes the drugs carboplatin, etoposide, and vincristine.
|Also of Interest|
Learn the basics about immunotherapy, a type of cancer treatment that helps your immune system fight cancer.
|Adolescents and Young Adults with Cancer|
Visit our gateway to information on cancer in adolescents and young adults, including treatment, follow-up care, coping, and related research.
Learn about the different types of pancreatic cancer and how they are treated, the latest research and statistics, and where to find suggestions for coping.